Equity Research, Broker Reports, and media content on FLEISCHEREI-BEDARF AG

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about FLEISCHEREI-BEDARF AG
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard
Login

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on FLEISCHEREI-BEDARF AG. We currently have 0 research reports from 0 professional analysts.

Open
N/A
Range Today
N/A
52 Week
0.00/0.00
Daily Volume
N/A
# Shares
0m
Daily Liquidity
0.0%
Pension Liability
Enterprise Value
n/am
Market Cap
0m
Latest PE (hist)
Div Yield

Latest News/RNS

(more news)
Date Source Announcement
Get free RNS email alerts

  • Frequency of research reports

     

  • Research reports on

    FLEISCHEREI-BEDARF AG

  • Providers covering

    FLEISCHEREI-BEDARF AG

  • 03 May 19

The Monthly May 2019

How small- and mid-cap quoted companies make a substantial contribution to markets, employment and tax revenues.

Companies: OPM AVO AJB ARBB CMH CLIG DPP FLTA GTLY GDR HAYD KOOV LWRF MCL MUR OXB PCA PHP RE/ STX SIXH TRX TON VTA W7L

  • 03 Apr 19

The Monthly April 2019

Although the focus of Hardman & Co is predominantly on companies in the smallto mid-sized market capitalisation range, when writing research reports, it is important to position them relative to the industry in which they operate. Apart from Japanese companies, all the major global pharmaceutical companies have reported full-year results for 2018 over the past few weeks; therefore, we have taken the opportunity to update our industry database and generate the first cut of global rankings for 2018. For an industry that requires a long investment cycle – it still takes, on average, 10 years from discovery to launch of a new drug – decisions made many years ago have important consequences on current financial results. Therefore, looking back at operational performance over 20 years reveals how different company strategies have panned out.

Companies: OPM AVO AJB AGY ARBB CMH CLIG CSH DNL GTLY HAYD KOOV LWRF MCL MUR NSF OXB PCA PHP RE/ REDX STX SCE SIXH TON VAL VTA W7L

  • 08 Jun 17

N+1 Singer - Small-cap quantitative research - Value screen periodic refresh and 9 focus stocks

We have completed another refresh of the value style screen, first established as of 12 May 2015. As usual the screen selected the 25 stocks exhibiting the most extreme value characteristics from our universe, and we have chosen 9 stocks to focus on. Since the last refresh as of 8 November 2016, the day before the US presidential election result was known, the screen has performed strongly (outperforming the small-cap index by 12.9pp on a weighted basis) with our focus stocks doing even better. The indication is that smaller value stocks perform well in a steady “risk on” environment. The new basket contains many UK consumer demand and emerging market plays. We find the latter exposure interesting at this juncture.

Companies: RAV GOAL VTU BILN INL AEP MAYA IPF OPM

  • 28 Feb 18

Upgrading to Buy on valuation and recovery grounds

In the context of the recovery thesis the 2017 finals are a good staging post. Most of the key goals were achieved last year and there is good top-line and cost saving momentum going into 2018. Geographical commentary is generally positive and leverage is becoming less of a concern. We are lowering our FY18/FY19 PBT expectations by 8-10% to largely reflect anticipated input cost/FX headwinds. Overall, we see value developing at current lows and upgrade to Buy.

Companies: Devro
  • 01 Mar 18

Strong year ending, sees better performance in FY18

Strong Q4 on the back of a rebound in Brazil as well as better performances in China and Colombia. The US remains soft, although improved vs. Q3. As positives, we note a better than expected margin progression. The improvment from quarter to quarter and positive FY18 outlook should be reassuring for shareholders.

Companies: AB INBEV
  • 15 Nov 18

Premier Foods - A more resilient business

Premier Foods’ H119 results demonstrate the business has become more resilient under the stewardship of outgoing CEO, Gavin Darby. Revenue growth of 1.0% in Q2 despite the hot summer was encouraging, and the UK relaunch of the Mr Kipling brand has clearly gone well. The news that Ambrosia may be sold suggests yet another step in the business transformation, although the price will determine the level of dilution and any change to net debt/EBITDA.

Companies: Premier Foods
  • 21 Nov 18

La Doria - A tough environment

The consumer environment remains tough for La Doria and the adverse weather conditions for the seasonal tomato campaign have led management to slightly edge down its FY18 profit outlook earlier this year. During 9M18, underlying sales were up 2%, which represents a slowdown from the +3.7% in H1. This was caused by a deceleration in growth in the “other lines” of the trading business during Q3, ie the non-core part. Management is forging ahead with its four-year investment plan and the Acerra plant has now closed. We trim our forecasts in line with the revised outlook and our fair value moves to €15.40 from €16.10.

Companies: La Doria
  • 14 Jan 19

Opportunity knocks

We are introducing our Best Ideas for 2019 and also review the performance of last year’s picks. We suggest ten solidly financed stocks with good business dynamics that ought to be considered for core portfolio holdings and six UK domestically focused stocks that our analysts believe should perform strongly in the event that uncertainties unwind. We also introduce a new style of research from N+1 Singer which presents a Company’s dynamics and metrics in a clear and concise manner and concentrates on the pivotal issues affecting that Company and an investment decision.

Companies: BCA CLIN CLG CBP DNLM EAH FDL FCRM FUTR GTLY INS GLE NICL SDL SPR TRI

  • 18 Apr 19

Cenkos: Venture Life Group Plc - Delivering on the strategy

Venture Life's full year results show a strong growing company generating profits and positioned to deliver both organic and M&A driven growth going forward. Revenues were £18.8m (trading update expectation £18.7m) and adjusted EBITDA was £2.7m versus our expected £2.3m. The 17% revenue growth was relatively evenly split between organic and M&A driven, demonstrating the potential of both aspects of the group's strategy. The company closed the year with a net cash position of £5.8m (2017A net debt £6.3m). We maintain our Buy recommendation.

Companies: Venture Life Group
  • 07 May 19

Q4 trading update

Distil has published a trading update on its Q4 performance, ahead of its prelims announcement next month. Revenues and volumes fell in Q4 as a result of Distil’s successful promotional activities in the peak Q3 period alongside the late timing of Easter. These declines were however in line with management expectations. Distil’s full year performance is therefore anticipated to be in line with current market expectations, and our forecasts remain unchanged. Distil has also announced the welcome launch of a new flavour variant to its successful RedLeg spiced rum brand. Sales of this brand extension, Caramelised Pineapple, will commence in June, initially with a soft launch through the on-trade channel only.

Companies: Distil
  • 08 May 19

LIBERUM: Science in Sport* - Catalysts being delivered at speed and early in the year

SiS is delivering on the promises made when it acquired PhD, leaving much of the year to leverage these opportunities. Innovation is bang-on-trend with today’s announcement of a launch of a vegan plant based bar.

Companies: Science In Sport
  • 09 May 19

LIBERUM: Origin Enterprises* - New financial targets underpin Buy rating

Origin Enterprises' Capital Markets Day presented an in-depth analysis of the company's strategy, markets and operations. It highlighted the strength of the Origin's position in the UK/Ireland and the scope for expansion in Brazil and Continental Europe.

Companies: Origin Enterprises